Título / Title

USE OF A SLOW-RELEASE INTRAVITREAL CLINDAMYCIN IMPLANT FOR THE MANAGEMENT OF OCULAR TOXOPLASMOSIS: A PHASE I CLINICAL TRIAL

Introdução / Purpose

To verify the safety of intravitreal clindamycin implant for ocular toxoplasmosis in patients that are intolerant or do not respond to traditional treatment

Material e Método / Methods

Phase I clinical trial to evaluate the safety of a 0.3 mg intravitreal implant of clindamycin. All patients with active ocular toxoplasmic retinochoroiditis 18-years old or older that had intolerance and/or did not respond to traditional oral treatment were invited to participate.. Comprehensive ophthalmologic evaluation was performed before intravitreal implant insertion and included ETDRS best-corrected visual acuity (BCVA), SD-optical coherence tomography (SD-OCT) and electroretinogram (ERG). The same tests were also performed one , three and six months after the procedure. The main safety parameters included changes in ERG wave amplitudes, eye inflammation and BCVA.

Resultados / Results

We reported here patients operated with the intravitreal clindamycin implant for ocular toxoplasmosis. Of the 4 cases reported, 2 obtained anatomical and functional success, 1 patient lost follow-up and 1 patient demonstrated no anatomic and functional improvement, due to a poor prognosis. There were no significant changes in electroretinography waves after treatment with the implant

Discussão e Conclusões / Conclusion

The present study describes the first study of intravitreal clindamycin implant for ocular toxoplasmosis in intolerant or refractory patients. This technique was associated with anatomic and visual improvement in most cases, and represents a safe alternative therapeutic.

Palavras Chave

Ocular toxoplasmosis / Clyndamycin implant

Area

CLINICAL RETINA